Despite a negative recommendation from the Oncologic Drugs Advisory Committee, Genentech Inc.'s Avastin (bevacizumab) gained accelerated approval from the FDA for use in combination with paclitaxel chemotherapy for the first-line treatment of metastatic HER2-negative breast cancer. (BioWorld Today)